---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010604"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:46:10.396284+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx reports 2022 results; announces Kite collaboration for CART-ddBCMA with $325M upfront

## Summary
- Strategic collaboration with Kite (Gilead): $225M upfront + $100M equity; co-commercialize in US, royalties ex-US.
- Phase 1 expansion data: 100% ORR, 71% CR/sCR in evaluable rrMM patients; no delayed neurotoxicity.
- Pivotal iMMagine-1 trial dosed; Phase 1 ACLX-002 for AML/MDS initiated.
- Cash $254.8M at Dec 31, 2022; plus $325M from Kite/Gilead in Jan 2023; expected to fund through BLA filing H1 2025.
- Net loss $188.7M for FY2022 vs $65.0M in 2021; R&D expenses $149.6M.

## SEC filing metadata
- accession: 0000950170-23-010604
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/0000950170-23-010604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/aclx-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010604
- JSON: https://secwatch.observer/filing/0000950170-23-010604.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010604.txt

## Key facts
- Earnings Releases
  Arcellx, Inc. reported fourth quarter and year ended December 31, 2022 results: net income Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188..
  - Period: fourth quarter and year ended December 31, 2022
  - Net income: Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188.
  - Result: reported results
  source text: Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/0000950170-23-010604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.